HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in a report issued on Thursday, May 11th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research analysts have also recently commented on INO. Zacks Investment Research upgraded Inovio Pharmaceuticals from a hold rating to a buy rating and set a $7.75 price objective on the stock in a research note on Friday, February 17th. Maxim Group reiterated a hold rating on shares of Inovio Pharmaceuticals in a research note on Thursday, February 23rd. Piper Jaffray Companies cut Inovio Pharmaceuticals from an overweight rating to a neutral rating and cut their price target for the stock from $13.00 to $9.00 in a research note on Thursday, March 16th. Aegis reiterated a buy rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, March 21st. Finally, Stifel Nicolaus reissued a buy rating and issued a $11.00 price objective on shares of Inovio Pharmaceuticals in a report on Tuesday, April 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $19.57.
Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at 7.84 on Thursday. The firm’s 50-day moving average price is $7.30 and its 200 day moving average price is $6.82. Inovio Pharmaceuticals has a one year low of $5.83 and a one year high of $11.61. The stock’s market cap is $585.08 million.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The company had revenue of $10.40 million for the quarter, compared to analysts’ expectations of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The firm’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. Equities research analysts expect that Inovio Pharmaceuticals will post ($1.10) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/06/17/inovio-pharmaceuticals-inc-ino-given-a-13-00-price-target-by-hc-wainwright-analysts-updated-updated-updated.html.
In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total transaction of $64,000.00. Following the sale, the director now directly owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jong Joseph Kim sold 147,180 shares of the business’s stock in a transaction on Friday, March 31st. The shares were sold at an average price of $6.54, for a total transaction of $962,557.20. Following the sale, the chief executive officer now directly owns 2,164,887 shares in the company, valued at $14,158,360.98. The disclosure for this sale can be found here. 10.60% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after buying an additional 226,861 shares during the period. Geode Capital Management LLC increased its position in Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock worth $3,708,000 after buying an additional 62,045 shares during the period. Bank of New York Mellon Corp increased its position in Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after buying an additional 11,765 shares during the period. Schwab Charles Investment Management Inc. increased its position in Inovio Pharmaceuticals by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 305,844 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 16,845 shares during the period. Finally, Stoneridge Investment Partners LLC increased its position in Inovio Pharmaceuticals by 0.8% in the first quarter. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company’s stock worth $1,684,000 after buying an additional 2,073 shares during the period. 27.73% of the stock is currently owned by institutional investors.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
What are top analysts saying about Inovio Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Inovio Pharmaceuticals Inc. and related companies.